Thus, this trimeric IMTX using the scFv against GPA33 as the target domain should be a good strategy to treat cancer, regarding its effectiveness on a monomeric form, and with the enhanced effectiveness of a trimeric design. The gene discussed is GPA33; the disease is cancer.